REPORT ID 3391

EMEA (Europe, Middle East and Africa) End-Stage Renal Disease (ESRD) Drugs Market Report 2019

Publish Date
2019
Pages
102
Format
Electronic (PDF)

In this report, the EMEA End-Stage Renal Disease (ESRD) Drugs market is valued at USD   XX million in 2019 and is expected to reach USD  XX million by the end of 2025, growing at a CAGR of  XX% between 2019 and 2025.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of End-Stage Renal Disease (ESRD) Drugs for these regions, from   2019 to 2025 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA End-Stage Renal Disease (ESRD) Drugs market competition by top manufacturers/players, with End-Stage Renal Disease (ESRD) Drugs sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    CTI BioPharma Corp
    Merck & Co Inc
    Novartis AG
    Prolong Pharmaceuticals LLC
    VESSL Therapeutics Ltd
    ...

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Calcium Succinate
    Mk-3866
    Pacritinib
    Sanguinate
    Tesidolumab
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Clinic
    ICU
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) End-Stage Renal Disease (ESRD) Drugs Market  Report 2019
1 End-Stage Renal Disease (ESRD) Drugs Overview
    1.1 Product Overview and Scope of End-Stage Renal Disease (ESRD) Drugs
    1.2 Classification of End-Stage Renal Disease (ESRD) Drugs
        1.2.1 EMEA End-Stage Renal Disease (ESRD) Drugs Market Size (Sales) Comparison by Type ( 2014-2024)
        1.2.2 EMEA End-Stage Renal Disease (ESRD) Drugs Market Size (Sales) Market Share by Type (Product Category)  in 2018
        1.2.3 Calcium Succinate
        1.2.4 Mk-3866
        1.2.5 Pacritinib
        1.2.6 Sanguinate
        1.2.7 Tesidolumab
        1.2.8 Others
    1.3 EMEA End-Stage Renal Disease (ESRD) Drugs Market by Application/End Users
        1.3.1 EMEA End-Stage Renal Disease (ESRD) Drugs Sales (Volume) and Market Share Comparison by Application ( 2014-2024
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 ICU
        1.3.5 Others
    1.4 EMEA End-Stage Renal Disease (ESRD) Drugs Market by Region
        1.4.1 EMEA End-Stage Renal Disease (ESRD) Drugs Market Size (Value) Comparison by Region ( 2014-2024)
        1.4.2 Europe Status and Prospect ( 2014-2024)
        1.4.3 Middle East Status and Prospect ( 2014-2024)
        1.4.4 Africa Status and Prospect ( 2014-2024)
    1.5 EMEA Market Size (Value and Volume) of End-Stage Renal Disease (ESRD) Drugs ( 2014-2024)
        1.5.1 EMEA End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2024)
        1.5.2 EMEA End-Stage Renal Disease (ESRD) Drugs Revenue and Growth Rate ( 2014-2024)

2 EMEA End-Stage Renal Disease (ESRD) Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA End-Stage Renal Disease (ESRD) Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA End-Stage Renal Disease (ESRD) Drugs Sales Volume and Market Share of Major Players ( 2014-2019)
        2.1.2 EMEA End-Stage Renal Disease (ESRD) Drugs Revenue and Share by Players ( 2014-2019)
        2.1.3 EMEA End-Stage Renal Disease (ESRD) Drugs Sale Price by Players ( 2014-2019)
    2.2 EMEA End-Stage Renal Disease (ESRD) Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA End-Stage Renal Disease (ESRD) Drugs Sales and Market Share by Type ( 2014-2019)
        2.2.2 EMEA End-Stage Renal Disease (ESRD) Drugs Revenue and Market Share by Type ( 2014-2019)
        2.2.3 EMEA End-Stage Renal Disease (ESRD) Drugs Sale Price by Type ( 2014-2019)
    2.3 EMEA End-Stage Renal Disease (ESRD) Drugs (Volume) by Application
    2.4 EMEA End-Stage Renal Disease (ESRD) Drugs (Volume and Value) by Region
        2.4.1 EMEA End-Stage Renal Disease (ESRD) Drugs Sales and Market Share by Region ( 2014-2019)
        2.4.2 EMEA End-Stage Renal Disease (ESRD) Drugs Revenue and Market Share by Region ( 2014-2019)
        2.4.3 EMEA End-Stage Renal Disease (ESRD) Drugs Sales Price by Region ( 2014-2019)

3 Europe End-Stage Renal Disease (ESRD) Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe End-Stage Renal Disease (ESRD) Drugs Sales and Value ( 2014-2019)
        3.1.1 Europe End-Stage Renal Disease (ESRD) Drugs Sales Volume and Growth Rate ( 2014-2019)
        3.1.2 Europe End-Stage Renal Disease (ESRD) Drugs Revenue and Growth Rate ( 2014-2019)
    3.2 Europe End-Stage Renal Disease (ESRD) Drugs Sales and Market Share by Type
    3.3 Europe End-Stage Renal Disease (ESRD) Drugs Sales and Market Share by Application
    3.4 Europe End-Stage Renal Disease (ESRD) Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe End-Stage Renal Disease (ESRD) Drugs Sales Volume by Countries ( 2014-2019)
        3.4.2 Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Countries ( 2014-2019)
        3.4.3 Germany End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)
        3.4.4 France End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)
        3.4.5 UK End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)
        3.4.6 Russia End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)
        3.4.7 Italy End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)
        3.4.8 Benelux End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)

4 Middle East End-Stage Renal Disease (ESRD) Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East End-Stage Renal Disease (ESRD) Drugs Sales and Value ( 2014-2019)
        4.1.1 Middle East End-Stage Renal Disease (ESRD) Drugs Sales Volume and Growth Rate ( 2014-2019)
        4.1.2 Middle East End-Stage Renal Disease (ESRD) Drugs Revenue and Growth Rate ( 2014-2019)
    4.2 Middle East End-Stage Renal Disease (ESRD) Drugs Sales and Market Share by Type
    4.3 Middle East End-Stage Renal Disease (ESRD) Drugs Sales and Market Share by Application
    4.4 Middle East End-Stage Renal Disease (ESRD) Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East End-Stage Renal Disease (ESRD) Drugs Sales Volume by Countries ( 2014-2019)
        4.4.2 Middle East End-Stage Renal Disease (ESRD) Drugs Revenue by Countries ( 2014-2019)
        4.4.3 Saudi Arabia End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)
        4.4.4 Israel End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)
        4.4.5 UAE End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)
        4.4.6 Iran End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)

5 Africa End-Stage Renal Disease (ESRD) Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa End-Stage Renal Disease (ESRD) Drugs Sales and Value ( 2014-2019)
        5.1.1 Africa End-Stage Renal Disease (ESRD) Drugs Sales Volume and Growth Rate ( 2014-2019)
        5.1.2 Africa End-Stage Renal Disease (ESRD) Drugs Revenue and Growth Rate ( 2014-2019)
    5.2 Africa End-Stage Renal Disease (ESRD) Drugs Sales and Market Share by Type
    5.3 Africa End-Stage Renal Disease (ESRD) Drugs Sales and Market Share by Application
    5.4 Africa End-Stage Renal Disease (ESRD) Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa End-Stage Renal Disease (ESRD) Drugs Sales Volume by Countries ( 2014-2019)
        5.4.2 Africa End-Stage Renal Disease (ESRD) Drugs Revenue by Countries ( 2014-2019)
        5.4.3 South Africa End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)
        5.4.4 Nigeria End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)
        5.4.5 Egypt End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)
        5.4.6 Algeria End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate ( 2014-2019)

6 EMEA End-Stage Renal Disease (ESRD) Drugs Manufacturers/Players Profiles and Sales Data
    6.1 CTI BioPharma Corp
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 End-Stage Renal Disease (ESRD) Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.1.4 Main Business/Business Overview
    6.2 Merck & Co Inc
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 End-Stage Renal Disease (ESRD) Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.2.4 Main Business/Business Overview
    6.3 Novartis AG
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 End-Stage Renal Disease (ESRD) Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.3.4 Main Business/Business Overview
    6.4 Prolong Pharmaceuticals LLC
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 End-Stage Renal Disease (ESRD) Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.4.4 Main Business/Business Overview
    6.5 VESSL Therapeutics Ltd
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 End-Stage Renal Disease (ESRD) Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.5.4 Main Business/Business Overview
    ...

7 End-Stage Renal Disease (ESRD) Drugs Manufacturing Cost Analysis
    7.1 End-Stage Renal Disease (ESRD) Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of End-Stage Renal Disease (ESRD) Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 End-Stage Renal Disease (ESRD) Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of End-Stage Renal Disease (ESRD) Drugs Major Manufacturers  in 2018
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA End-Stage Renal Disease (ESRD) Drugs Market Forecast ( 2019-2025)
    11.1 EMEA End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Price Forecast ( 2019-2025)
        11.1.1 EMEA End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate Forecast ( 2019-2025)
        11.1.2 EMEA End-Stage Renal Disease (ESRD) Drugs Revenue and Growth Rate Forecast ( 2019-2025)
        11.1.3 EMEA End-Stage Renal Disease (ESRD) Drugs Price and Trend Forecast ( 2019-2025)
    11.2 EMEA End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.3 Europe End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.4 Middle Eastt End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.5 Africa End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.6 EMEA End-Stage Renal Disease (ESRD) Drugs Sales Forecast by Type ( 2019-2025)
    11.7 EMEA End-Stage Renal Disease (ESRD) Drugs Sales Forecast by Application ( 2019-2025)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer